MOSCOW, 23 APR – RIA Novosti. Chinese scientists have discovered that the antiviral drug “Arbidol” and combination of “Lopinavir/Ritonavir” (LPV/r) are not effective means for the treatment of patients with mild-to-moderate forms COVID-19. The results of a study published in the journal Med.
the Experts decided to study LPV/r and “Arbidol” after their inclusion in a list of potential funds from COVID-19 National Commission on public health of China. The experiment involved 86 patients with mild to moderate forms COVID-19, of which 34 people took the combination of LPV/r, 35 patients – “Arbidol”, while the other 17 patients were not treated with any antiviral drugs.
All three groups demonstrated similar dynamics over time in one and two weeks. Thus, patients were not observed any differences in the level of temperature reduction, mitigate cough or improve the results of computer tomography of the chest. However, patients in the groups who took LPV/r, and “Arbidol”, experienced a number of side effects, such as diarrhea, nausea and loss of appetite, while patients from the third group have no obvious side effects were observed.
“We found that neither LPV/r nor “Arbidol” can not improve the clinical picture in patients, and that they can cause some side effects,” said one of the study’s authors, Deputy Director of the Center for infectious disease hospital in Guangzhou Linhua Lee.
According to him, the results of the experiment indicate that physicians should be careful to use these drugs. The scientist urged the experts to continue work on finding a truly effective cure COVID-19, pointing out that conclusions about the effectiveness of a means needs to be confirmed by rigorous clinical trials.
the world health organization on 11 March announced the outbreak of a new coronavirus infection COVID-19 pandemic. According to the latest who data, the number of cases COVID-19 in the world reached almost 2.5 million people, more than 169 thousand people died.
the Latest data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.
